Developing Products for Important Medical Needs
On May 7, 2018, Impax Laboratories, Inc. combined with Amneal Pharmaceuticals, Inc. (NYSE:AMRX) to create a dynamic company powered by a robust U.S. generics business and growing branded franchise. Today, we are working to integrate our business into the new Amneal and are excited about our future as one company.
Amneal + Impax Specialty R&D
Our Specialty Pharma business, continuing to operate as Impax, delivers medicines focused on meeting important medical needs across therapeutic categories, including central nervous system disorders, parasitic infections and other therapeutic areas.
We are focused on the continued growth and expansion of our product portfolio through internal development as well as through acquisitions and late-stage and next-generation product partnership opportunities.